GRFS (Grifols) EPS without NRI: $0.72 (TTM As of Mar. 2026)


GRFS Grifols SA GRFS
84 GF Score
Price $7.32
GF Value $8.87
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Grifols EPS without NRI?

Grifols GRFS -0.95% 84 EPS without NRI is $0.72 as of Mar. 2026. GuruFocus rates GRFS with a GF Score™ of 84/100 and a GF Value™ of $8.87 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 784 Drug Manufacturers companies, Grifols ranks better than 80.36% on this metric.

Grifols's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $0.12. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $0.72.

During the past 12 months, Grifols's average earnings per share (NRI) Growth Rate was 114.20% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 35.30% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -7.80% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was -14.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Grifols's EPS without NRI or its related term are showing as below:

GRFS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -54.6   Med: 6   Max: 86.8
Current: 35.3

During the past 13 years, Grifols's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 86.80% per year. The lowest was -54.60% per year. And the median was 6.00% per year.

GRFS's 3-Year EPS without NRI Growth Rate is ranked better than
80.36% of 784 companies
in the Drug Manufacturers industry
Industry Median: 9.7 vs GRFS: 35.30

Grifols's EPS (Diluted) for the three months ended in Mar. 2026 was $0.12. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.71.

Grifols's EPS (Basic) for the three months ended in Mar. 2026 was $0.12. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.71.


Grifols  (NAS:GRFS) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Grifols EPS without NRI Related Terms


Grifols EPS without NRI Historical Data

* Premium members only.

The historical data trend for Grifols's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols EPS without NRI Chart

Grifols Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.34 0.26 0.08 0.30 0.72

Grifols Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.21 0.22 0.17 0.12

GRFS vs LLY, JNJ, ABBV: EPS without NRI Comparison

For the Drug Manufacturers - General subindustry, Grifols's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Grifols's PE Ratio without NRI falls into.


GRFS
84GF Score
Grifols SA GRFS
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grifols EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $0.72 mean?
Grifols (GRFS) has a EPS without NRI of $0.72 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Grifols and its competitors. According to the industry distribution chart, Grifols ranks #154 out of 784 companies in the Drug Manufacturers industry, placing it in the top 19.6%.
Is Grifols' EPS without NRI too high?
Grifols' current EPS without NRI is $0.72. The Drug Manufacturers industry median EPS without NRI is 9.70. Grifols' value of $0.72 is 92.6% below this industry median. Based on the distribution chart, Grifols ranks #154 out of 784 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grifols has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' EPS without NRI compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #154 out of 784 companies for EPS without NRI. This places Grifols in the top 20% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 9.70. Grifols' value of $0.72 is 92.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 784 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current EPS without NRI of $0.72 is 92.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Grifols and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current EPS without NRI is $0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.87, compared to a current price of $7.32 — trading 17.5% below its estimated fair value. The current EPS without NRI is $0.72 and 92.6% below the Drug Manufacturers industry median of 9.70. Grifols' overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Grifols (GRFS), the current EPS without NRI is $0.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grifols (GRFS) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of $7.32 is trading 17.5% below its estimated GF Value™ of $8.87. GuruFocus considers Grifols to be Modestly Undervalued.

Key valuation signals for GRFS:

  • EPS without NRI: $0.72
  • GF Value™: $8.87 vs. price of $7.32 (17.5% below fair value)
  • GF Score™: 84/100 with 6 warning signs
  • Industry Position: 92.6% below the Drug Manufacturers median (#154 of 784)

No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
84GF Score

Get the complete analysis for GRFS

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.32
Price
$8.87
GF Value